Kornimate/medical-research-clean huggingface dataset:
effect of magnesium supplementation on patients with diabetic nephropathy

Conditions: Diabetes

Summary: this is a double-blind randomized clinical trial which will start at june 2014 and end on june 2015 in isfahan city. serum creatinine level is considered as a key variable and the sample size calculated 80 persons (40 persons for control group and 40 persons for patient group). patients aged more than 18 years old with diabetic nephropathy having fasting blood sugar more than 126 mg/dl and proteinuria 30-300 mg/dl (microalbuminuria) and glomerular filtration rate more than 90 ml/min will be chosen. patient group will receive magnesium supplement (250 milligram) and the other group will receive placebo which is similar to the magnesium tablets in color, odor and appearance both for 12 weeks. all subjects will complete 4 physical activity and 4 dietary records. outcome measurements including metabolic, renal and inflammatory profiles will be measured at the beginning and end of the study as well as anthropometric measurements.

this is a double-blind randomized clinical trial which will start at june 2014 and end on june 2015 in isfahan city. serum creatinine level is considered as a key variable and the sample size calculated 80 persons (40 persons for control group and 40 persons for patient group).

Eligibility criteria:
inclusion criteria: * more than 18 years old * diabetic nephropathy * fasting blood sugar more than 126 milligram per deciliter * proteinuria 30-300 milligram per deciliter (microalbuminuria) * glomerular filtration rate more than 90 milliliter per minute * not having hyperthyroidism or hypothyroidism * not having any feverish urinary tract infection * not using any kind of drug including cigarette * not having any liver disease * not having any cancer and inflammatory diseases * not having more than 4 kilogram weight loss during last 3 months * not using any magnesium-rich supplement exclusion criteria: * changing medicine dose * not having adherence (using less than 75 percent of medicines) * cardiac arrhythmias

Keywords: diabetic nephropathy renal function insulin resistance metabolic profile serum magnesium level
rectus femoris tenotomy versus botulinum toxin a for stiff knee gait after stroke

Conditions: Stroke; Spasticity

Summary: stiff knee gait is defined as the lack of knee flexion in the swing phase of gait. stiff knee gait is a frequent condition among stroke patients leading to reduce gait speed and increase energy cost. in association with neuro-rehabilitation, botulinum toxin a injections in the rectus femoris is recommended. however, the botulinum toxin a effect is transient necessitating repeated injections. the aim of this study is to compare the benefit of the rectus femoris tenotomy in comparison with botulinum toxin a injections according to the 3 domains of the international classification of functioning disability and health of the world health organisation

introduction stroke is the third cause of death and the leading cause of handicap among industrialized countries. spasticity and co-contraction of the rectus femoris muscle following stroke is responsible for a lack of knee flexion in the swing phase of gait named stiff knee gait. the rectus femoris spasticity is usually treated by oral medications, physical therapy and botulinum toxin a injections (1,2). as botulinum toxin a has a transient effect, injections must be repeated supporting to promote a permanent surgical treatment such as the rectus femoris tenotomy (3). however, no study has evaluate neither compare the effect of the rectus femoris tenotomy on gait and on the 3 domains of the international classification of functioning disability and health . objective to compare the effect of the rectus femoris tenotomy and of the botulinum toxin a injections for stiff knee gait after stroke according to the 3 domains of the international classification of functioning disability and health methods the investigators will recruited 20 chronic stroke patients presenting with stiff knee gait. the patients will be randomly assigned to a surgical group treated by rectus femoris tenotomy (10 patients) and to a medical group treated by rectus femoris botulinum toxin a injections. patients will be assessed before treatment, 2 months and 6 months after treatment by an assessor blinded therapist among the 3 domains of the international classification of functioning disability and health perspective the investigator hope to demonstrate the effectiveness of the rectus femoris tenotomy as a treatment of stiff knee gait after stroke

Eligibility criteria:
inclusion criteria: * stroke lasting for more than 6 months * stiff knee gait * rectus femoris spasticity (\> ashworth 2) * transient improvement with previous botulinum toxine a injection in the rectus femoris * stiff knee gait improved after rectus femoris diagnostic motor nere block * able to walk on treadmill exclusion criteria: * pregnant women * botulinum toxin a injections in the rectus femoris \< 6 months * previous surgery for stiff knee gait

Keywords: stroke muscle spasticity stiff knee gait botulinum toxin tenotomy
exploration of anticoagulation program in cerebral aneurysm and arteriovenous malformations with hybrid operation 2

Conditions: Cerebral Aneurysm; Arteriovenous Malformations

Summary: in the stage of randomized controlled study, our purpose is to obtain the intraoperative anticoagulation program supported by evidence-based medicine.

this study is divided into anticoagulation program in cerebral aneurysm with hybrid operation and anticoagulation program in cerebral arteriovenous malformations with hybrid operation two parts, and each part divide into two stage, on the stage of registration study. this study is a multi-center, single-blind, prospective cohort study. record the patient's intraoperative activated coagulation time changes in detail, to observe the effect of activated coagulation time maintenance level on hemorrhage event rate of intraoperative and postoperative 48 hours, purpose to find out the safety range of activated coagulation time level in cerebral aneurysm and arteriovenous malformations with hybrid operation. on the stage of randomized controlled study. this study is a multicenter, single-blind, prospective, randomized controlled study. patients is divided into intraoperative standard dose group of heparin sodium and low dose group of heparin sodium randomly. to observe the effect of different anticoagulation regimens on activated coagulation time safety coverage rate during surgery, and finally develop a scientific and effective intraoperative anticoagulant therapy program.

Eligibility criteria:
inclusion criteria: 1.all patients undergoing hybird surgery. exclusion criteria: 1. poor general condition , severe primary disease, surgical contraindications 2. patient or family refused surgery 3. fusiform aneurysm,traumatic aneurysm,infectious aneurysms 4. combined with other hemorrhagic cerebrovascular disease 5. combined with malignant brain tumor 6. perinatal, pregnancy 7. patients unwilling to participate in the trial

Keywords: hybrid operation cerebral aneurysm arteriovenous malformations anticoagulation
a study of modified stem cells in stable ischemic stroke

Conditions: Chronic Ischemic Stroke

Summary: the primary purpose of the clinical study is to determine the safety of a modified stem cell sb623 when administered to chronic, stable ischemic stroke patients. a second purpose is to determine whether sb623 might improve stroke symptoms. chronic, stable ischemic stroke patients must be between 6 and 60 months after their stroke, and with only this one prior stroke, and with no further improvement from physical therapy.

chronic, stable stroke patients have no existing alternative treatments after rehabilitation therapy. sb623, a modified stem cell preparation, has been shown to improve motor function when administered in animal models of stable stroke. safety studies in animals have shown no adverse events attributed to sb623. patients who meet the entry criteria for this study will have regular examinations, radiological evaluations (ct, mri, pet), and be followed for two years. regular neurological evaluations will also be done using standard questionnaires, with occasional video recording if improvements are evident. key entry criteria for this study, in addition to 6-60 months post-ischemic stroke, include moderately severe symptoms--e.g., difficulty standing or walking, and/or difficulty using arms or hands, and/or speech impediments.

Eligibility criteria:
inclusion criteria: * documented history of one completed ischemic stroke in subcortical region of mca or lenticulostriate artery with or without cortical involvement * between 6 and 60 months post-stroke, and having a motor neurological deficit * no significant further improvement with physical therapy/rehabilitation * able and willing to undergo computed tomography (ct), magnetic resonance imaging (mri), and positron-emission tomography (pet) scans of the head exclusion criteria: * history of more than 1 symptomatic stroke * history of seizures * history or presence of any other major neurological disease * myocardial infarction within prior 6 mos. * known presence of any malignancy except squamous or basal cell carcinoma of the skin * participation in any other investigational trial within 4 weeks of initial screening and within 7 weeks of study entry * contraindications to head ct, mri, or pet * pregnant or lactating

Keywords: chronic stroke stable stroke ischemic stroke fixed motor deficits
effect of sarpogrelate, a serotonin receptor antagonist, on coronary artery disease

Conditions: Coronary Artery Disease

Summary: this is a prospective interventional study to assess the effect of sarpogrelate compared with aspirin in korean type 2 diabetic patients with atherosclerosis.

type 2 diabetes has been increased exponentially, arousing serious economic, social and health repercussions. also, macrovascular complications of diabetes such as myocardial infarct or stroke have been increased. individuals with diabetes have a greater risk of cardiovascular disease (cvd), approximately two to four times than that of those without diabetes. currently, the u.s. food and drug administration requires demonstration that new anti-hyperglycemic agents do not increase cardiovascular risk. the comprehensive and multifactorial management in type 2 diabetes, which includes control of hypertension, dyslipidemia and obesity, is known to significantly reduce the risk of cvd as shown in steno-2 study. however, most anti-diabetic agents currently used in clinical practice do not seem to provide enough cardiovascular protection.

Eligibility criteria:
inclusion criteria: * type 2 diabetes with hba1c ≥ 6.5% at screening visit * male or female between 30 and 80 years of age * coronary artery stenosis: 10-75% without no evidence of acute coronary syndrome * no history of previous myocardial infarction exclusion criteria: * systolic blood pressure / diastolic blood pressure \> 160/110 mmhg * congestive heart failure * allergy to radiocontrast dye * allergy to aspirin or sarpogrelate * acute bleeding * history of ulcer bleeding * got/gpt \> 100/100 * other antiplatelet medication
atherosclerosis in rheumatoid arthritis

Conditions: Atherosclerosis; Cardiovascular Diseases; Heart Diseases; Inflammation; Arthritis, Rheumatoid

Summary: to test the theory that accelerated inflammation-promoted atherosclerosis occurs in patients with rheumatoid arthritis (ra).

background: premature cardiovascular disease is a major cause of mortality in rheumatoid arthritis (ra). the mechanisms underlying accelerated atherosclerosis and its relationship to inflammation in ra are poorly understood. recent studies indicate that inflammation through the effects of inflammatory cytokines, and oxidative stress, through lipid peroxidation, are important in the pathogenesis of atherosclerosis. the study's hypothesis is that accelerated, inflammation-promoted atherosclerosis occurs in ra. design narrative: the study tests the hypotheses: 1) that structural and functional vascular damage is more frequent and more severe in patients with established ra than matched controls and is related to cumulative disease severity; 2) that this impairment of vascular integrity is associated with clinical and laboratory markers of inflammation, plasma homocysteine concentrations, and oxidative stress. to address these two hypotheses the relationship between longstanding inflammation and vascular integrity will be determined in a cross-sectional study of 75 patients with established ra in whom prospectively obtained clinical data are available for 15 years, and 75 matched non-ra controls. endothelium-dependent, flow-mediated dilation of the brachial artery measured by ultrasound, and coronary calcium volume measured by electron beam computed tomography (ebct) will provide functional and structural measures of vascular integrity, respectively. f2-isoprostane excretion, a reliable index of lipid peroxidation in vivo, homocysteine and lipid concentrations will be measured. vascular integrity, oxidative stress, lipids and homocysteine will be compared in controls and ra patients. in the ra patients the relationship between ra activity and damage indices obtained over 15 years and vascular function and damage measures will be determined. using the same techniques we will address hypothesis 3) that the rate of progression of vascular disease in patients with early ra can be altered by control of inflammation. in a prospective cohort of 100 patients with early ra receiving usual clinical care and 100 matched non-ra controls followed over 24 months the relationship between clinical and biochemical measures of inflammation and vascular integrity will be determined by comparing "responders" and "non-responders". these studies will provide a basic understanding of the interrelationship between inflammation, lipids, oxidative stress and vascular damage, and will suggest strategies for reversing or preventing such damage in ra and, potentially, other diseases.

Eligibility criteria:
must meet acr criteria for ra
a study to evaluate the safety and efficacy of topically applied tv 45070 ointment in patients with postherpetic neuralgia (phn)

Conditions: Postherpetic Neuralgia

Summary: this is a study to evaluate the safety and efficacy of 4% and 8% w/w tv 45070 ointment compared with placebo ointment applied topically and twice daily to the area of phn pain for 4 weeks in patients with phn


Eligibility criteria:
inclusion criteria: * patient has chronic postherpetic neuralgia (phn), defined as pain present for more than 6 months and less than 10 years after onset of herpes zoster skin rash affecting a single dermatome. patients with more than 1 involved dermatome may also be included, provided the affected dermatomes are contiguous. * patient is ≥18 years of age, with a body mass index (bmi) between 18 and 34 kg/m2, inclusive, at the screening visit. * if the patient is a woman and is fertile, the patient is not pregnant and has negative pregnancy tests at both the screening and randomization visits, and agrees to use an acceptable method of contraception for the duration of the study, including follow-up. * if the patient is a man and is capable of producing offspring, the patient must agree to use an acceptable method of contraception, unless the partner cannot become pregnant for the duration of the study, including follow-up. * patient must sign the written informed consent form (icf) for the study and be willing to comply with all study procedures and restrictions. * patient must be judged by the investigator to be medically healthy (except for phn) and able to participate in the study * other criteria apply, please contact the investigator for more information exclusion criteria: * patient has any other severe pain that might confound assessment or self-evaluation of pain due to phn. * patient has phn affecting the face (trigeminal nerve distribution). * patient has a history, in the judgment of the investigator, of inadequate response to more than 3 adequate courses of treatment with other medications used to treat neuropathic pain (eg, tricyclic antidepressants, serotonin-norepinephrine reuptake inhibitors, anticonvulsants, topical lidocaine, and/or topical capsaicin). * patient is taking oral analgesics (either opioid or non-opioid) or is receiving topical therapy such as the 5% topical lidocaine patch for the treatment of pain and is unwilling or unable to complete a washout period during which the patient will discontinue analgesic therapy or topical pain therapy. * patient has been treated with topical capsaicin at any time in the past 6 months for neuropathic pain. * patient has a history of fibromyalgia. * other criteria apply, please contact the investigator for more information
concurrent carboplatin and reduced dose craniospinal radiation for medulloblastoma and primitive neuroectodermal tumor (pnet)

Conditions: Metastatic Medulloblastoma; High Risk Supratentorial PNET; Metastatic PNET

Summary: the purpose of this study is to study the efficacy of the combination of reduced dose craniospinal radiation (reduced from standard of care dosing at 36 gy to 24 gy) with concurrent carboplatin and vincristine administration for metastatic classical histology medulloblastomas and high-risk supratentorial pnets and metastatic pnets.


Eligibility criteria:
inclusion criteria: * age greater than 3 years and less than 25 years * patients with classic histology or desmoplastic histology metastatic medulloblastoma by histological diagnosis and by head and spine mri. * patients with high-risk supratentorial, non-metastatic, pnet * patients with metastatic pnet * newly diagnosed patients who have not received prior therapy, with the exception of one short course of emergent chemotherapy in newly presenting patients with neurological compromise per provider decision * only patients who are expected to survive at least 6 weeks will be eligible for this study. exclusion criteria: * patients who are pregnant may not be treated on this study * patients with anaplastic histology
the genetic and the functional study of dna repair system and the susceptibility to rheumatoid arthritis

Conditions: Rheumatoid Arthritis

Summary: this study is valuable for the understanding the role of dna repair system plays in the progression of rheumatoid arthritis and for the development of new therapeutic modality in the future.

rheumatoid arthritis (ra) is a symmetric polyarticular arthritis that primarily affects the small diarthrodial joints of the hands and feet. in addition to inflammation in the synovium, which is the joint lining, the aggressive front of tissue called pannus invades and destroys local articular structures. the synovium is normally a relatively acellular structure with a delicate intimal lining. ra is also a chronic autoimmune disease and can lead to deformities and severe disabilities, due to irreversible damage of tendons, joints, and bones. it is known that ra can be considered as a complex genetic disease and many "disease-risk" genes or "disease-protective" genes can be involved. numerous studies reported the association of il-6, il-8 genes with systemic lupus erythematosus (sle) and the association of hla-dr gene polymorphisms with ra. in addition, the chronic inflammatory process of ra is mediated through cytokines network, which leads to induce some destructive enzymes, like matrix metalloprotieases, in the cellular synovial tissue of joints. although ra is a common arthritis with a prevalence of 1% in taiwan, the pathogenesis is still incompletely studied, especially in dna repair relative genes. in this proposal, we would like to perform the following experiments: 1. study the associations of the polymorphisms of dna repair relative genes and the susceptibility to ra; 2. study the associations of the copy number variation (cnv) of dna repair relative genes and the susceptibility to ra; 3. functional assay in dna repair relative genes and compare it with the copy number variation (cnv), genotype and/or haplotype in ra patients; so far, we have analyzed the association between ra and several snps of mutyh in dna repair systems. we also analyzed the relationship between the snps results and ra using the pathological features. these data are helpful to clarify the susceptibility of ra patients with the genotype and/or haplotype in dna repair system. this study is valuable for the understanding the role of dna repair system plays in the progression of rheumatoid arthritis and for the development of new therapeutic modality in the future.

Eligibility criteria:
inclusion criteria: * participant has sang a consent form. exclusion criteria: * participant is under 18 years old.

Keywords: rheumatoid arthritis (ra) dna repair system polymorphism susceptibility copy number variation (cnv)
novamin on streptococcus mutans count in dental plaque of high caries risk children

Conditions: Dental Plaque; Dental Caries

Summary: inhibition of streptococcus mutans can be effective to prevent caries in high caries-risk children. the aim of the study is to evaluate the effect of novamin on streptococcus mutans in the plaque of high caries-risk children.


Eligibility criteria:
inclusion criteria: * medically healthy children. * no erupting first permanent molars. * high caries risk children; have visible cavities or have a visible plaque on their teeth. * cooperative (positive or definitely positive), according to frankl's behavior rating scale exclusion criteria: * history of intake of antibiotics for the past 3-4 weeks. * history of professional fluoride treatment over 2 weeks before the study. * children with tooth structure defects. * children unable to return for recall visits
automatic diagnosis of early esophageal squamous neoplasia using pcle with ai

Conditions: Esophageal Neoplasms; Artificial Intelligence; Confocal Laser Endomicroscopy

Summary: detection and differentiation of esophageal squamous neoplasia (esn) are of value in improving patient outcomes. probe-based confocal laser endomicroscopy (pcle) can diagnose esn accurately.however this requires much experience, which limits the application of pcle. the investigators designed a computer-aided diagnosis program using deep neural network to make diagnosis automatically in pcle examination and contrast its performance with endoscopists.


Eligibility criteria:
inclusion criteria: * aged between 18 and 80; * agree to give written informed consent； exclusion criteria: * advanced esophageal squamous cell carcinoma or esophageal stenosis; * having no suspicious lesion of esn found by wle and iee * known allergy to fluorescein sodium; * having coagulopathy or impaired renal function; * being pregnant or breastfeeding.
3d breast ultrasound elastography in patients under neoadjuvant chemotherapy

Conditions: Malignant Breast Tumours

Summary: breast ultrasound elastography is a complementary technique permitting a better characterization of breast lesions. 3d breast ultrasound elastography is a novel technique permitting a volumetric calculation of lesion stiffness. this could be particularly useful in patients with large breast tumors under pre-operative chemotherapy

3d breast ultrasound elastography provides volumetric lesion stiffness details in real time. 3d acquisition is compared to breast mri in order to evaluate volume measurements calculated in ultrasound. lesion elasticity is calculated in 3 planes with immediate reconstruction. the purpose of this prospective study is to evaluate the feasibility of this technique and compare the results to those of breast mri. for women receiving preoperative chemotherapy, this technique will be evaluated with regard to tumour shrinkage and lesion elasticity modifications under treatment.

Eligibility criteria:
inclusion criteria: * patients having already undergone a breast mri * patients presenting with breast lesions measuring between20-50mm in ultrasound exclusion criteria: * multifocal lesions * history of breast cancer * breast implants * inflammatory breast disease * pregnancy